Publications by authors named "M Nishitsuji"
Article Synopsis
- * Researchers analyzed RNA-seq data from 465 blood samples, uncovering 1169 expression quantitative trait loci (eQTLs) and 1549 splice QTLs (sQTLs) linked to COVID-19 severity, including immune-related expressions.
- * The study highlights the impact of disease severity on gene expression, identifying specific eQTLs that interact with COVID-19 phenotypes, and provides an extensive resource for understanding gene regulation in response to the virus.
Article Synopsis
- Researchers conducted a genome-wide association study (GWAS) with 2,393 COVID-19 patients and 3,289 controls in Japan, identifying a specific genetic variant (rs60200309-A) on chromosome 5 linked to severe cases in individuals under 65.
- The variant is more common in East Asians and associated with reduced expression of the DOCK2 gene, which was found to be lower in severe COVID-19 cases, particularly in non-classical monocytes.
- Additionally, inhibiting DOCK2 in hamsters worsened pneumonia symptoms, indicating its potential as a biomarker and therapeutic target for severe COVID-19.
Background: Immune checkpoint inhibitor (ICI) monotherapy is more effective than cytotoxic chemotherapy in improving overall survival (OS) among patients with advanced-stage non-small cell lung cancer (NSCLC). Recently, chemotherapy combined with ICI has been found to yield good outcomes. However, ICI monotherapy is still considered an important treatment option.
View Article and Find Full Text PDFBackground: Pleurodesis is the standard of care for non-small cell lung cancer (NSCLC) patients with symptomatic malignant pleural effusion (MPE). However, there is no standard management for MPE uncontrolled by pleurodesis. Most patients with unsuccessful MPE control are unable to receive effective chemotherapy.
View Article and Find Full Text PDFArticle Synopsis
- Alectinib significantly improves survival in patients with ALK rearrangement-positive non-small cell lung cancer (NSCLC) who have a poor performance status (PS), showing consistent benefits even with central nervous system metastases.
- The LOGiK 1401 study involved 18 patients with a PS of 2, 3, or 4, revealing a median survival time of 30.3 months and a 3-year overall survival rate of 43.8%.
- The results indicate that alectinib is an effective treatment option for these patients, who typically do not qualify for chemotherapy.